机器人活体供肾切除术相比手辅助腹腔镜入路与术后阿片类药物用量减少相关
本研究回顾性比较本中心150例机器人供肾切除术(RDN)与150例手辅助腹腔镜供肾切除术(LDN)的术后镇痛用药。RDN组术后阿片类药物总用量(MME)显著低于LDN组(27.1 vs 46.3,P<0.0001),术后住院时间更短(1.69天 vs 1.98天,P=0.0003),非阿片类药物使用、并发症及再入院率无差异。
要点
- RDN组术后阿片类药物总用量(MME)显著低于LDN组(27.1 vs 46.3,P<0.0001)。
- RDN组术后住院时间短于LDN组(1.69天 vs 1.98天,P=0.0003)。
- 两组非阿片类药物使用、并发症及再入院率无差异。
核心结论
- RDN与手辅助LDN安全性相当,并提供术后阿片类药物需求更低和住院时间更短的额外获益。
研究设计与样本
- 回顾性综述本中心300例活体供肾切除术,比较150例RDN与 contemporaneous 150例手辅助LDN。
- 收集术后住院期间(从术后到达外科病房至出院)阿片类和非阿片类镇痛数据,阿片剂量转换为吗啡毫克当量(MME)。
- 所有患者术后均按活体供肾切除术患者标准化ERAS路径管理。
主要发现
- RDN组与LDN组供者年龄、性别和BMI无显著差异。
- 术后阿片类药物总用量(MME)RDN组显著低于LDN组(27.1 vs 46.3;P<0.0001)。
- 术后第1天阿片用量RDN组显著低于LDN组(8.6 vs 17.0;P<0.05),术后第2天RDN组显著低于LDN组(3.9 vs 10;P<0.05)。
- RDN组术后住院时间短于LDN组(1.69天 vs 1.98天;P=0.0003)。
- 两组非阿片类药物使用、并发症和再入院率无差异。
关键数值与推荐
- 术后阿片总用量(MME):RDN组27.1 vs LDN组46.3(P<0.0001)。
- 术后第1天阿片用量:RDN组8.6 vs LDN组17.0(P<0.05)。
- 术后第2天阿片用量:RDN组3.9 vs LDN组10(P<0.05)。
- 术后住院时间:RDN组1.69天 vs LDN组1.98天(P=0.0003)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Robotic donor nephrectomy (RDN) has emerged as a safe alternative to laparoscopic donor nephrectomy (LDN). Having previously demonstrated comparable efficacy, this study aims to examine postoperative analgesia use (opioid and non-opioid) in the two groups. METHODS: We conducted a retrospective review of 300 living donor nephrectomies performed at our center, comparing 150 RDN's with a contemporary cohort of 150 hand-assisted LDN's. In addition to clinical and demographic information, data on postoperative inpatient opioid and non-opioid analgesia (from patient's arrival to the surgical floor after surgery till the time of discharge) was collected. Opioid dosages were standardized by conversion to morphine milligram equivalents (MME). All patients were managed post-operatively under a standardized ERAS pathway for living donor nephrectomy patients. RESULTS: There were no significant differences in donor age, gender, and BMI between RDN and LDN groups. Total post-operative opioid use (MME's) was significantly lower in RDN patients (RDN 27.1 vs. LDN 46.3; P < 0.0001). Breakdown of opioid use with post-operative (POD) day demonstrated significantly lower use in RDN group on POD1 (RDN 8.6 vs. LDN 17.0; P < 0.05), and POD2 (RDN 3.9 vs LDN 10; P < 0.05). RDN patients had a shorter post-operative length of stay (LOS) (RDN 1.69 days vs. LDN 1.98; P = 0.0003). There were no differences between groups in non-opioid medication use, complications, and readmission rates. CONCLUSION: RDN has comparable safety to hand-assist LDN and offers additional benefits of lower postoperative opioid requirement and a shorter hospital LOS.
引用
- Kiani AZ, Progar K, Hill AL, et al. Robotic living donor nephrectomy is associated with reduced post-operative opioid use compared to hand-assisted laparoscopic approach. Surg Endosc. 2024. PMID: 38777895. doi:10.1007/s00464-024-10925-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。